Please ensure Javascript is enabled for purposes of website accessibility

Is Achillion a Bad News Buy Post-Bloodbath?

By Dave Williamson and Max Macaluso - Sep 30, 2013 at 6:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares were cut in half after its hepatitis C drug continues on clinical hold.

This episode of The Motley Fool's Market Checkup drills down on the hottest headlines and biggest market movers in the health-care sector. 

In this video, health-care analysts David Williamson and Max Macaluso discuss Achillion Pharmaceuticals' no good, very bad day. The company announced after the market closed on Friday that its hepatitis C drug sovaprevir would remain on clinical hold. Shares have been slashed in half by investors.

Achillion is in a tough position. It has a broad range of hep C drugs, but it is far back in development from its deep-pocketed competitors. Gilead and Johnson & Johnson have drugs under FDA review right now, while Gilead and AbbVie each plans to offer interferon free "drug cocktails" soon after. Combine that with a litany of safety-related clinical holds in next-gen hep-C treatments and investors hoping for a quick resolution for what looked to be a drug-to-drug related interaction are left disappointed.

David and Max take a closer look at how this delay impacts Achillion, why investors were even more skittish after the conference call, and if the stock's sell-off made it a bad news buy.

David Williamson owns shares of AbbVie and Johnson & JohnsonFollow David on Twitter @MotleyDavid. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. It recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$170.29 (-0.48%) $0.82
Achillion Pharmaceuticals, Inc. Stock Quote
Achillion Pharmaceuticals, Inc.
ACHN
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$61.46 (0.61%) $0.37
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$73.22 (1.52%) $1.10
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$138.85 (0.58%) $0.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.